Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: A systematic review and meta-analysis

International Clinical Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 59-69

  Gartlehner, Gerald ^a   Hansen, Richard A ^a   Carey, Timothy S ^a   Lohr, Kathleen N ^b   Gaynes, Bradley N ^c   Randolph, Leah C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Compliance; Depression; Discontinuation rates; Side effects

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PAXIL XR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADVERSE DRUG REACTION; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCINFO; REVIEW; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIANSERIN; OUTPATIENTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TREATMENT REFUSAL;

EID: 14844361982     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200503000-00001     Document Type: Review

References (45)

1. Alves C, Cachola I, Brandao J (1999). Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry 5:57-63.
2. Anderson IM (2001). Meta-analytical studies on new antidepressants. Br Med Bull 57:161-178.
3. Anderson IM, Tomenson BM (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310:1433-1438.
4. Anonymous (2004). Depressing research. Lancet 363:1335.
5. Armitage R, Yonkers K, Cole D, Rush AJ (1997). A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17:161-168.
6. Ballus C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, et al. (2000). The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 15:43-48.
7. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, Vester-Blokland ED (2003). Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 23:358-364.
8. Benkert O, Szegedi A, Kohnen R (2000). Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656-663.
9. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. (2002). Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357-366.
10. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, Ascher JA (1999). Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11:205-215.
11. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, et al. (2001). A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23:1040-1058.
12. Costa e Silva J (1998). Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59: 352-357.
13. Croft H, Settle EJ, Houser T, Batey SR, Donahue RM, Ascher JA (1999). A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21:643-658.
14. De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, et al. (2002). Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5:1 15-120.
15. Dierick M, Ravizza L, Realini R, Martin A (1996). A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 20:57-71.
16. Egger M, Smith GD, Altman DG (2001). Systematic Reviews in Health Care, 2nd edn. London: BMJ Publishing Group.
17. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
18. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR* D) study. Psychiatr Clin North Am 26:457-494.
19. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CX (1996). Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57 (suppl 2):53-62.
20. Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG (1991). Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52:329-335.
21. Gartlehner G, Hansen RA, Kahwati L, Lohr KN, Gaynes BN, Carey TS (2004). Drug class review on second generation antidepressants. Drug Effectiveness Review Project: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm.
22. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2004). Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Library (Cochrane Review). Chichester: John Wiley & Sons, Ltd.
23. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ (1997). A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192.
24. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003). The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475.
25. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D (2001). Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20:21-35.
26. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ (2003). A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 64:921-926.
27. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA (1997). Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58:532-537.
28. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
29. McPartlin GM, Reynolds A, Anderson C, Casoy J (1998). A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry 4:127-132.
30. Mehtonen OP, Sogaard J, Roponen P, Behnke K (2000). Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 61: 95-100.
31. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
32. Mulrow C, Williams JWJ, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, Cornell J (2000). Efficacy of newer medications for treating depression in primary care patients. Am J Med 108:54-64.
33. National Health Service Centre for Reviews and Dissemination (2001). Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4, 2nd edn. York: University of York.
34. Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR (2003). Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 64:875-882.
35. Rudolph RL, Feiger AD (1999). A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171-181.
36. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, et al. (1998). Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44: 3-14.
37. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GMJ (2002). Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10:541-550.
38. Silverstone PH, Ravindran A (1999). Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 60:22-28.
39. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683-687.
40. Song F, Glenny AM, Altman DG (2000). Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 21:488-497.
41. Song F, Altman DG, Glenny AM, Deeks JJ (2003). Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472.
42. Tylee A, Beaumont G, Bowden MW, Reynolds A (1997). A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry 3:51-58.
43. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L (2003). A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 18:133-141.
44. Weihs KL, Settle ECJ, Batey SR, Houser TL, Donahue RM, Ascher JA (2000). Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61:196-202.
45. Williams JW, Mulrow CD, Chiquette E, Noel PH, Augilar C, Cornell J (2000). A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annal Intern Med 132:743-756.